中国科学技术信息研究所--国家工程技术数字图书馆

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer

[期刊]

《癌症通讯(英文)》 2019年1期

原文获取收藏分享

作者	Zhi-Qiang Wang Fei Zhang Ting Deng Le Zhang Fen Feng Feng-Hua Wang Wei Wang De-Shen Wang Hui-Yan Luo Rui-Hua Xu Yi Ba Yu-Hong Li
期刊名称	《癌症通讯(英文)》
期刊英文名称	《癌症通讯（英文）》
页码/总页数	P.245-252 / 8
语种/中图分类号	汉语 / R73
关键词	Pancreatic cancer Metastatic Chemotherapy FOLFIRINOX Dose modification First-line Multicenter Overall response rate Efficacy Safety

相关论文

Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

Metastatic pancreatic cancer： Is there a light at the end ofthe tunnel？

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study

PD-1/L1 inhibitors can improve but not replace chemotherapy for advanced urothelial carcinoma:A systematic review and network meta-analysis

相关机构

安徽医科大学

温州医科大学

哈尔滨医科大学

广州医科大学

相关作者

相关关键词